1992
DOI: 10.1089/hyb.1992.11.61
|View full text |Cite
|
Sign up to set email alerts
|

Production of Novel Monoclonal Antibodies Against Rabbit Platelet Factor Four

Abstract: Ten hybridomas producing monoclonal antibodies (Mabs) against rabbit platelet factor 4 (PF4) were obtained from the fusion of splenocytes from mice immunized with purified rabbit PF4 and NSO mouse myeloma cells. When the reactivities of these monoclonal antibodies were determined by enzyme-linked immunosorbent assay and immunoblotting with human and rabbit PF4, they showed a high degree of specificity. Only one Mab recognized an epitope common to the human and rabbit molecules, the other nine reacted only with… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

1993
1993
2011
2011

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 26 publications
0
2
0
Order By: Relevance
“…Myeloma cells are known to be efficient fusion partners for the production of hybrids Milstein, 1975, 1976). As a consequence, NS0 cells have been used for a number of years as fusion partners for the production of hybridoma cells producing monoclonal antibodies (Cazzola et al, 1992; Cloeck- aert Lyaku et al, 1992;Richards et al, 1992;Zumla et al, 1992;Cloeckaert et al, 1993;Thole and Jakob, 1993;Porro et al, 1994;Green et al, 1995;Ghebrehiwet et al, 1996). However, NS0 cells are now an important host cell for the engineered production of recombinant proteins in their own right, particularly in combination with the GS selection system.…”
Section: Ns0 Cell Historymentioning
confidence: 99%
“…Myeloma cells are known to be efficient fusion partners for the production of hybrids Milstein, 1975, 1976). As a consequence, NS0 cells have been used for a number of years as fusion partners for the production of hybridoma cells producing monoclonal antibodies (Cazzola et al, 1992; Cloeck- aert Lyaku et al, 1992;Richards et al, 1992;Zumla et al, 1992;Cloeckaert et al, 1993;Thole and Jakob, 1993;Porro et al, 1994;Green et al, 1995;Ghebrehiwet et al, 1996). However, NS0 cells are now an important host cell for the engineered production of recombinant proteins in their own right, particularly in combination with the GS selection system.…”
Section: Ns0 Cell Historymentioning
confidence: 99%
“…Since its development over 20 years ago, the NS0 cell line (Barnes, 2000;Galfre and Milstein, 1981) has been used extensively to produce monoclonal antibodies, either as a fusion partner in hybridoma technology (Cazzola et al, 1992;Lyaku et al, 1992;Novak et al, 1986;Richards et al, 1992) or as a result of transfection for recombinant protein production (Andersen and Krummen, 2002;Bebbington et al, 1992;Lin et al, 1998;Werge et al, 1992). It is one of the primary mammalian host cell lines used for expression of therapeutic antibodies (Chadd and Chamow, 2001;Whitford, 2003;Wurm, 2004).…”
Section: Introductionmentioning
confidence: 99%